Evaluation of IL 12B Genetic Polymorphism (rs3213094)
Trial Parameters
Brief Summary
Psoriasis is a skin disorder that is chronic proliferative and inflammatory in nature. Extensor surfaces, scalp, and lumbosacral area are covered in erythematous plaques with silvery scales. The disease can also impair the eyes and joints. It has no cure. Because of their low quality of life, many psoriasis patients experience depression. In addition to the cutaneous manifestations, it is associated with an increased risk of psoriatic arthritis, depression and cardiovascular disease.
Eligibility Criteria
Inclusion Criteria: \- Patients having psoriasis diagnosed clinically for at least 6 months and who have a severity grade of severe, defined as a Psoriasis Area and Severity Index (PASI) score greater than 10, and involvement of greater than 10% of the body surface area (BSA) with psoriatic arthritis. Exclusion Criteria: * Patients with other autoimmune or inflammatory conditions (e.g., rheumatoid arthritis, lupus). * Pregnancy and lactation. * Patients currently undergoing any treatment other than Humira. * Patients with known genetic disorders affect immune system function. * Patients were undergoing any treatment other than Humira in the last 6 months. * Patients with active infections, including tuberculosis or chronic viral infections (e.g., hepatitis B or C, HIV). * Patients with contraindication to Humira. * Renal \&Vascular diseases